Business News

After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program – FierceBiotech

After being bounced by Bristol Myers after its Celgene takeover, Jounce is courting again, this time an early romance with Gilead Sciences.
BMS made the final cut to a longstanding immuno-oncology pact with Jounce back in June, coming as it swung the ax on unwanted projects from its recent Celgene buy.
Jounce is now bouncing back, however with a new deal from Gilead. The biobucks are not as high as the $2.6 billion it originally penned with Celgene, but $685 million is nothing to be sniffed a…

Click here to view the original article.

Related Posts

You might also like ...